MedTrace Logo

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

NCT00750555 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-02-26

Study results available
· View outcomes & findings →

Summary

Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

Conditions

Interventions

DRUG

Erlotinib

150 mg per day orally until disease progression occurs, up to a maximum of 12 months

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Geisinger Clinic

    lead OTHER

Principal Investigators

  • Amy Law, MD · Geisinger Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00750555 on ClinicalTrials.gov